paloma-1 study of palbociclib in er , her2-, breast cancer
Published 9 years ago • 1.1K plays • Length 8:25Download video MP4
Download video MP3
Similar videos
-
6:29
study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
-
1:29
dr. finn on the phase iii paloma-2 trial in er breast cancer
-
2:45
paloma-3: phase 3 trial of fulvestrant with palbociclib for metastatic breast cancer
-
5:04
paloma-3: palbociclib and fulvestrant for hr-/her metastatic breast cancer
-
3:02
paloma-3: palbociclib plus fulvestrant in hormone receptor-positive advanced breast cancer
-
3:30
final results from pallas: adjuvant palbociclib in hr /her2- early breast cancer
-
39:21
bcfnz webinar: palbociclib (ibrance) for advanced or metastatic hr breast cancer - nz update
-
6:38
palbociclib shows improved pfs but not improved os for er her2- mbc patients
-
2:46
preliminary data on op-1250 palbociclib in advanced/metastatic er /her- breast cancer
-
2:02
palbociclib combined with fulvestrant in relapsed metastatic hr /her2- breast cancer
-
2:46
ameera-3: amcenestrant does not improve pfs in er /her2- breast cancer
-
13:22
palbociclib and breast cancer
-
6:56
analyses from paloma-3 study, including os data for hr breast cancer
-
2:04
dr. richard finn discusses palbociclib for patients with advanced breast cancer
-
0:37
debu tripathy, md discusses the paloma-2 trial outcomes in er /her2- advanced breast cancer
-
3:46
harmonia clinical trial
-
5:43
cdk 4/6 inhibitor, palbociclib, for the treatment of metastatic breast cancer
-
5:10
paloma-3: overall survival (os) with palbociclib plus fulvestrant in hr ,her2_ abc
-
5:00
penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer